The messenger RNA drug developer, backed by Monsanto, Merck & Co, GlaxoSmithKline, Pfizer and Merck Group, has raised more than $121m in its initial public offering.

Johns Hopkins-backed biopharmaceutical developer Allakos has filed for a $75m initial public offering after raising more than $160m in equity funding.

UC Investment Office-backed gene expression technology developer Constellation Pharmaceuticals has filed for an $86.3m initial public offering.

The Merck GHI-backed medical device developer had raised $120m in funding prior to its initial public offering.

Onyx Therapeutics-backed autoimmune drug developer Kezar Life Sciences has closed its initial public offering at $86.3m.

The transplant-based medicine developer, backed by Alphabet, Partners Healthcare and Access Industries, floated in the middle of its range.

The UCL spinout has priced its shares at the top of its range and secured $150m in proceeds, up from its initial target of $100m.

The Northwestern University-backed neurologic disorder therapy developer floated at the top of its range, increasing the share volume at the same time.

The Nan Fung-backed neurologic disorder therapy developer floated at the top of its range, increasing the share volume at the same time.